Skip to content
August 11, 2026

K2 Therapeutics Appoints Dr. Ying Huang as Chief Executive Officer and Announces $50 Million Seed Financing

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue